---
schema_version: "secwatch.filing_event.v1"
accession: "0001485003-22-000158"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:07:39.632420+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sesen Bio obtains final court approval for derivative lawsuit settlement

## Summary
- U.S. District Court for Massachusetts granted final approval on Nov 8, 2022 for settlement of consolidated derivative lawsuits.
- Settlement covers In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538, and Tang v. Sesen Bio, Inc., Case No. 2281-cv-00135.
- Company also disclosed securities class action settlement hearing set for Jan 23, 2023 in Southern District of New York.
- Previously, court granted preliminary approval on Sep 2, 2022; terms in Aug 30, 2022 8-K.

## SEC filing metadata
- accession: 0001485003-22-000158
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000148500322000158/0001485003-22-000158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000148500322000158/sesn-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001485003-22-000158
- JSON: https://secwatch.observer/filing/0001485003-22-000158.json
- Plain text: https://secwatch.observer/filing/0001485003-22-000158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.